02:20 PM EST - Oncolytics Biotech Inc. : Announced an update on the proposed design of its planned registration-directed clinical trial in first-line pancreatic ductal adenocarcinoma (PDAC). The Company is currently scheduled to meet with the U.S. Food and Drug Administration (FDA) in mid-November 2025 to advance study details. Oncolytics Biotech Inc.
shares N.ONCY are trading up 15 cents at $1.44.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=6648545338379621
